Pulseless electrical activity risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
The administration of [[beta blockers]] and [[calcium channel blockers]] is associated with an increased risk of PEA. This may be due to their effect on Ca / troponin interactions, and their inhibition of myocardial contractility. | The administration of [[beta blockers]] and [[calcium channel blockers]] is associated with an increased risk of PEA. This may be due to their effect on Ca / troponin interactions, and their inhibition of myocardial contractility. | ||
Revision as of 20:19, 21 February 2013
|
Pulseless electrical activity Microchapters |
|
Differentiating Pulseless Electrical Activity from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Pulseless electrical activity risk factors On the Web |
|
American Roentgen Ray Society Images of Pulseless electrical activity risk factors |
|
Directions to Hospitals Treating Pulseless electrical activity |
|
Risk calculators and risk factors for Pulseless electrical activity risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The administration of beta blockers and calcium channel blockers is associated with an increased risk of PEA. This may be due to their effect on Ca / troponin interactions, and their inhibition of myocardial contractility.